U.S. AI in Oncology Market Size, Share, Trends and Forecast, 2026–2034

Industry Dynamics

• The rising prevalence of cancer patients has resulted in increased use of AI in oncology in the U.S.
• The continuous improvement and expansion of healthcare infrastructure is another factor shaping the market landscape.
• Growing use of generative AI for target identification and target therapies is creating several market opportunities.
• Lengthy FDA regulatory approvals may present market challenges.

Industry Trend

A.I. technologies have the potential to revolutionize various aspects of cancer care, from early detection to treatment selection, monitoring, and personalized medicine. AI-powered algorithms can analyze medical imaging data, such as mammograms, C.T. scans, and MRIs, to identify suspicious lesions or tumors at an early stage. These tools help radiologists and oncologists detect cancer more accurately and efficiently, due to timely intervention and improved patient outcomes.

The significant strides in technology within the realm of cancer diagnostics have been pivotal. Innovations such as advanced imaging techniques, molecular diagnostics, and genomic profiling have revolutionized the way cancer is detected and managed. These technological advancements not only enable earlier detection but also facilitate more precise and personalized treatment strategies, thereby enhancing patient outcomes.

Source: Polaris Market Research Analysis

To Understand More About this Research: Download Sample Report

Furthermore, the continuous improvement and expansion of healthcare infrastructure In the U.S. have played a crucial role in driving market growth. Increased investment in healthcare facilities, coupled with initiatives to enhance access to diagnostic services, has bolstered the demand for cancer diagnostic tools and services. Additionally, there is a growing awareness among individuals about the importance of early detection in improving cancer prognosis. This heightened awareness, coupled with advancements in screening programs and campaigns, has led to a surge in the demand for early and accurate cancer diagnosis. As a result, the U.S. A.I. in oncology market size is estimated to increase during the forecast period.

The company has embarked on a significant collaborative effort, marking a bold step towards innovation in its operations. By embracing a comprehensive strategy geared towards broadening market reach, engaging with new demographics, and fostering sustainable growth in a dynamic business landscape, the company is primed for success. Leveraging the synergies of investment, technology, innovation, and strategic planning, it stands well-equipped to uphold its competitive edge and emerge as a frontrunner in its sector. Consequently, the U.S. A.I. in oncology market share is anticipated to witness substantial growth during the forecast period.

• For instance, in January 2024, NVIDIA Corporation collaborated with Deepcell to expedite the integration of generative A.I. into single-cell research, focusing on areas such as stem cells, cancer, and cell therapies.

A.I. technologies are being increasingly utilized in cancer research to analyze large datasets, identify biomarkers, and uncover new insights into the molecular mechanisms underlying cancer. This includes the development of A.I. algorithms for genomic analysis, drug discovery, and predictive modeling of cancer progression and response to therapy. Hence, the U.S. A.I. in oncology market share is estimated to increase during the forecast period.

AI in Oncology Market in Simple Terms

Artificial intelligence (AI) in oncology uses advanced computer systems to assist health care professionals in diagnosing and treating cancers. Cancer imaging AI helps detect cancer at an early stage by analyzing medical imaging results, pathological slides, genomic information, and patient records. This helps personalize patients' treatment plans.

How AI in Oncology Works?

Patient Data Collection: Patients’ medical history, imaging tests, pathological reports, laboratory reports, and genomic data are collected from multiple healthcare providers.

Data Analysis Using AI: The AI algorithm analyzes imaging tests, pathological information, genomic data, and clinical data to identify patterns, abnormal findings, and disease features.

Tumor Identification and Cancer Risk Evaluation: The software can detect potential tumors and estimate the likelihood of cancer and its progression using machine learning techniques.

Treatment Suggestion: The AI suggests personalized treatment based on the patient’s tumor features, past medical history, and clinical practice.

Clinical Evaluation and Validation: An oncologist reviews the suggestions made by AI and validates them.

Personalized Cancer Treatment and Monitoring: The treatment suggested is prescribed to the patient, whereas AI keeps monitoring the patient’s condition and treatment.

Traditional Oncology vs. AI-Powered Oncology

Parameter	Traditional Oncology	AI-Based Oncology
Diagnostic Time	Dependent largely on the assessment of experts through manual processes.	Fast analysis of medical images, pathology, and patient information.
Accuracy	The accuracy depends on the experience of physicians and manual interpretation.	Helps physicians interpret complex patterns of diseases.
Data Analysis	Insufficient capability to handle large and complex datasets simultaneously.	Analyze imaging, pathology, genomics, and clinical information at once.
Treatment Planning	Disease treatment plans depend heavily on physician experience.	Able to incorporate numerous patient information for developing treatment plans.
Workflow Efficiency	Several administrative and diagnostic tasks are manual in nature.	Streamlines administrative and diagnostic processes.
Decision Making	The decision-making is dependent on the physician's experience and evidence base.	Provides evidence-based analytics for decision making.

Source: Polaris Market Research Analysis

What are the market drivers driving the demand for the U.S. AI in oncology market?

Increasing prevalence of cancer patients is projected to spur market demand.

The market's growth is attributed to the increasing prevalence of cancer, technological advancements in cancer diagnostics and healthcare infrastructure, and an increasing demand for early and accurate diagnosis of cancer. Significant strides in technology within the realm of cancer diagnostics have been pivotal. Innovations such as advanced imaging techniques, molecular diagnostics, and genomic profiling have revolutionized the way cancer is detected and managed. These technological advancements not only enable earlier detection but also facilitate more precise and personalized treatment strategies, thereby enhancing patient outcomes.

Furthermore, the continuous improvement and expansion of healthcare infrastructure have played a crucial role in driving market growth. Increased investment in healthcare facilities, coupled with initiatives to enhance access to diagnostic services, has bolstered the demand for cancer diagnostic tools and services. Additionally, there is a growing awareness among individuals about the importance of early detection in improving cancer prognosis. This heightened awareness, coupled with advancements in screening programs and campaigns, has led to a surge in the demand for early and accurate cancer diagnosis.

AI Enabling Precision Oncology

Artificial intelligence technologies are contributing to precision oncology solutions by enabling tumor characterization, analysis of genomic information, integration of patients' medical history, and assessment of treatment outcomes to deliver personalized care. With machine learning algorithms, it’s possible to determine the best possible treatment for each individual patient, as well as predict the treatment outcome and the future course of the disease. This way, medical professionals can design their treatment plan and make effective use of available health care facilities. With greater availability of genomic and clinical data, the role of artificial intelligence in treatment selection is growing.

Digital Pathology and AI-Based Tumor Analysis

The use of digital pathology combined with AI has enabled improved diagnosis of cancer through increased accuracy and speed. AI-based tools help in analyzing the high-definition pathology images to determine the presence of cancer cells, classify tumors, analyze the tissue samples, and detect biomarkers. Digital pathology tools improve the consistency of the diagnosis process, help pathologists with their daily practice, and allow for rapid reporting, thus helping in delivering improved diagnoses and treatment plans. AI tools can also help in determining complicated cases requiring specialized attention.

AI Accelerating Oncology Drug Discovery

Artificial Intelligence is being employed in speeding up oncology drug discovery by pharmaceutical and biotech firms through analyzing huge sets of biological and clinical data to come up with targets for drugs. Artificial intelligence algorithms are capable of predicting drug effects, enhancing compound selection, and assisting with biomarker discovery, thereby making the process of drug development less costly and time-consuming. This enhances research efficiency and makes the development of cancer medicines a more efficient process.

Which factor is restraining the demand for U.S. AI in oncology?

Regulatory Challenges are likely to impede the market growth.

The introduction of AI technologies in healthcare, including oncology, is subject to regulatory oversight by agencies such as the Food and Drug Administration (FDA) in the United States. Obtaining regulatory approval for AI-based medical devices and software can be a lengthy and complex process, involving rigorous testing and validation to ensure safety, efficacy, and accuracy. Delays in regulatory approval can hinder the adoption of AI solutions by healthcare providers, limiting their availability and accessibility to patients. Hence, the U.S. AI in the oncology market is likely to impede the growth.

Source: Polaris Market Research Analysis

Report Segmentation

The market is primarily segmented based on component, cancer type, treatment type.

By Component	By Cancer Type	By Treatment Type
Software Solutions Hardware Services	Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Brain Tumor Others	Chemotherapy Radiotherapy Immunotherapy Others

Source: Polaris Market Research Analysis

Category Wise Insights

By Cancer Type Insights

Based on cancer type analysis, the market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, brain tumor, and others. Breast cancer accounted for the largest market share in 2023. This dominance is primarily driven by the escalating prevalence of breast cancer within the population.

According to the Centers for Disease Control and Prevention (CDC), while deaths from breast cancer have decreased over time, it still ranks as the second due to cause of cancer-related deaths among women overall and the primary cause among Hispanic women. Annually, in the United States, breast cancer is diagnosed in women, with around 240,000 cases and approximately 2,100 in men. The disease claims the lives of about 500 men and 42,000 women in the U.S. each year.

Consequently, there's a growing necessity for the introduction of innovative solutions to aid in the detection, diagnosis, and treatment of breast cancer. This trend towards advanced technology adoption is a key driver propelling the overall growth of the U.S. A.I. in the oncology market.

By Treatment Type Analysis

Based on treatment type analysis, the market is segmented into chemotherapy, radiotherapy, immunotherapy, and others. The chemotherapy segment accounted for the largest market share in 2023. Chemotherapy involves the administration of drugs to destroy cancer cells or inhibit their growth and is often a cornerstone of cancer treatment regimens.

With the integration of artificial intelligence (A.I.) technologies, such as machine learning algorithms and predictive analytics, healthcare providers can optimize chemotherapy treatment protocols, personalize dosing regimens, and predict patient responses more accurately. This enhances treatment outcomes, minimizes adverse effects, and improves overall patient care, contributing to the dominance of the chemotherapy segment within the A.I. in the Oncology market in the U.S.

Chemotherapy is a widely utilized cancer treatment, with an estimated 60% of Stage 4 bladder cancer patients undergoing this procedure, as reported by the American Cancer Society. The integration of A.I. into chemotherapy treatment helps healthcare professionals create personalized digital profiles for patients, allowing the customization of dosage during treatment.

Source: Polaris Market Research Analysis

Competitive Landscape

In the U.S. AI in oncology market, competition is evident through fragmentation, with numerous players vying for market share. Leading service providers in this field consistently upgrade their technologies to stay ahead, prioritizing efficiency, reliability, and safety. To secure a strong foothold in the market, these entities stress the importance of strategic partnerships, continual product improvements, and collaborative initiatives to outpace their industry peers.

Some of the major players operating in the US market include:

• Azra AI
• ConcertAI
• GE HealthCare
• IBM
• Intel Corporation
• Median Technologies
• NVIDIA Corporation
• PathAI
• Siemens Healthcare GmbH

Future Outlook

The AI in oncology market is anticipated to see robust growth due to increased adoption of AI-driven diagnostic, precision medicine, and digital pathology tools. The ongoing advancements in deep learning, machine learning in oncology, genomics, and predictive analytics are expected to further enhance cancer screening and treatment techniques. In addition, growing investment by healthcare organizations, biotech companies, and technology vendors is likely to speed up innovations in the field, while more integration of AI with EHRs and clinical decision support systems would further increase the significance of AI in cancer care.

Recent Developments

• April 2026: GE HealthCare today announced an expanded collaboration with DeepHealth, Inc. The partnership aims to extend access to DeepHealth’s AI-powered breast cancer screening solutions(source: deephealth.com).
• March 2026: Royal Philips revealed the expansion of its digital pathology portfolio with new cloud-enabled capabilities. The company stated that capabilities are designed to help healthcare organizations scale digital diagnostics and advance their transformation to fully digital workflows(source: usa.philips.com).
• In March 2025, PathAI entered into a partnership with the Canadian Center for Regenerative Medicine (CCRM) to jointly develop an AI-driven platform for cell therapy manufacturing and quality control, with the goal of accelerating personalized cancer treatments.
• In January 2024, PathAI introduced an expansion of six additional oncology indications for PathExplore, an AI-driven pathology panel utilized for the spatial analysis of the tumor microenvironment (TME).

Report Coverage

The U.S. AI in oncology market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.

The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, component, cancer type, treatment type, and their futuristic growth opportunities.

U.S. AI In Oncology Market Report Scope

Report Attributes	Details
Market size value in 2025	USD 1.41 Billion
Market size value in 2026	USD 1.79 Billion
Revenue forecast in 2034	USD 12.25 Billion
CAGR	27.10% from 2026 – 2034
Base year	2025
Historical data	2021 – 2024
Forecast period	2026 – 2034
Quantitative units	Revenue in USD billion and CAGR from 2026 to 2034
Segments covered	By Component, By Cancer Type, By Treatment Type,
Customization	Report customization as per your requirements with respect to countries, region and segmentation.

Source: Polaris Market Research Analysis